Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

NFX

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) in Idiopathic Pulmonary Fibrosis (IPF) for tranilast lystate, the active drug substance enabled for inhaled delivery in Nuformix’s NXP002 lead programme.

The FDA grants ODD for investigational treatments for rare diseases, such as IPF, defined as affecting fewer than 200,000 people in the United States.  ODD qualifies the developer for certain incentives with the goal of accelerating drug development for patients, including tax credits for clinical trials or qualified clinical testing costs, a waiver of the Prescription Drug User Fee Act application fee when a marketing application is submitted, and the potential to receive seven years of marketing exclusivity upon product approval.

Dr Dan Gooding, Executive Director, Nuformix, said: “We are delighted to receive confirmation that Orphan Drug Designation has been granted by the FDA for our NXP002 programme in IPF, a high-mortality rare disease, in urgent need of new treatments. The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with and I look forward to providing further updates in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Nuformix to acquire Biovara in deal to combine two respiratory drug programmes

Nuformix has agreed heads of terms to acquire Biovara Limited in a proposed share-for-share deal, adding its LipAprep treatment...

Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation

Nuformix plc reports statistically significant reductions in TGF-β/SMAD signalling following inhaled administration of NXP002 in a preclinical study, supporting...

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis,...

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons....

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions....

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the...

Search